Dr. Kulke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
820 Harrison Street
Boston Medical Center
Boston, MA 02118Phone+1 617-638-7012- Is this information wrong?
Summary
- Matthew H. Kulke, MD is the Chief of Hematology/Oncology at Boston Medical Center, Co-Director of the BU/BMC Cancer Center and the Zoltan Kohn Professor at Boston University Chobanian & Avedisian School of Medicine (Boston University Chobanian & Avedisian School of Medicine). He is internationally recognized for his expertise in neuroendocrine tumors and has led numerous national and international clinical trials resulting in new drugs and therapies for this indication. He is a past chair of the NCCN neuroendocrine tumor guidelines committee and the North American Neuroendocrine Tumor Society. Dr. Kulke has published more than 200 peer-reviewed articles in his area of expertise.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997- Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
University of California San Francisco School of MedicineClass of 1992
Princeton UniversityBA, Molecular Biology, Summa Cum Laude, 1983 - 1987
Certifications & Licensure
MA State Medical License 1995 - 2026
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas Start of enrollment: 2001 Jan 01
- Tarceva and Capecitabine for Pancreatic Cancer Start of enrollment: 2003 Oct 01
- Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer Start of enrollment: 2004 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39...Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, Eric Raymond, Philippe Ruszniewski, Matthew H Kulke, Enrique Grande, Rocío García Carbonero, Daniel Caste...> ;European Journal of Cancer. 2024 Apr 11
- Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.Laura Burns, Hanna Tukachinsky, Kira Raskina, Richard S P Huang, Alexa B Schrock, Jacob Sands, Matthew H Kulke, Geoffrey R Oxnard, Umit Tapan> ;Lung Cancer. 2024 Feb 1
- 1 citationsIntertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.Samantha E Hoffman, Todd W Dowrey, Carlos Villacorta Martin, Kevin Bi, Breanna Titchen, Shreya Johri, Laura DelloStritto, Miraj Patel, Colin Mackichan, Stephanie Inga,...> ;Science Advances. 2023 Sep 29
- Join now to see all
Press Mentions
TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome DiarrheaOctober 27th, 2021- Boston Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital Formalize Cancer Clinical Trial CollaborationSeptember 29th, 2020
- Gerald Denis Named Shipley Prostate Cancer Research ProfessorAugust 20th, 2020
- Join now to see all
Grant Support
- Molecular And Genetic Analysis Of Neuroendocrine Tumor Risk And SurvivalNational Cancer Institute2011
- Molecular Analysis Of Esophageal Cancer SurvivalNational Cancer Institute2003–2007
Hospital Affiliations
Boston Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
